Trial Profile
Adalimumab, azathioprine or mesalazine for the prevention of postoperative recurrence of Crohn's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine; Mesalazine
- Indications Crohn's disease
- Focus Therapeutic Use
- 26 Jun 2013 New trial record
- 18 May 2013 Primary endpoint 'Disease-recurrence-rate' has been met.
- 18 May 2013 Results presented at the Digestive Disease Week 2013.